| CellCept® and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus A Standard-Dose CNI
|
(Roche)
|
04-Jun-2008 |
| Final Results of the CellCept® Spare the Nephron (STN) Study Shows Maintenance Therapy Is Associated with Improved Renal Function
|
(Roche)
|
02-Jun-2008 |
| Pertuzumab With Herceptin Shows Impressive Results in Women With Advanced HER2-Positive Breast Cancer
|
(Roche)
|
30-May-2008 |
| Actemra Inhibits Joint Damage and Improves Physical Function of Patients With Rheumatoid Arthritis
|
(Roche)
|
09-May-2008 |
| Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C
|
(Roche)
|
28-Apr-2008 |
| Actemra Approved in Japan to Treat Patients With Rheumatoid Arthritis
|
(Roche)
|
16-Apr-2008 |
| Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody Obtained Approval for Indications of Rheumatoid Arthritis, Polyarticular-Course Juvenile Idiopathic Arthritis and Systemic-Onset Juvenile Idiopathic Arthritis
|
(Chugai)
|
16-Apr-2008 |
| OSI Pharmaceuticals Summarizes Data Presented at the Annual Meeting of the American Association for Cancer Research
|
(OSI Pharmaceuticals)
|
16-Apr-2008 |
| International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
|
(Roche)
|
20-Mar-2008 |
| Femara® Helps Protect Against Return of Breast Cancer Even When Treatment Starts Several Years After Completing Tamoxifen Therapy
|
(Novartis)
|
10-Mar-2008 |
| Combination Therapy of Anti-cancer Agents, Xeloda®, Elplat® and Avastin®, and Monotherapy of Xeloda® Filed for Advanced or Recurrent Colorectal Cancer
|
(Chugai)
|
29-Feb-2008 |
| Herceptin Approved in Japan for Early Treatment in Patients with HER2-Positive Breast Cancer
|
(Roche)
|
29-Feb-2008 |
| Anti-Cancer Agent Herceptin® Obtained Approval for a New Indication for Adjuvant Therapy in Breast Cancer that Overexpresses HER2
|
(Chugai)
|
29-Feb-2008 |
| Roche Responds to Announcement of “IDEAL” Hepatitis C Trial Results
|
(Roche)
|
14-Jan-2008 |
| Anti-Cancer Agent Xeloda® Obtained Approval for a New Indication for Postoperative Adjuvant Chemotherapy for Colon Cancer and Overseas Dosage and Administration
|
(Chugai)
|
14-Dec-2007 |
| On the Launch and Measures for Proper Use of the Anti-Cancer Agent Tarceva® Tablet
|
(Chugai)
|
14-Dec-2007 |
| OSI Pharmaceuticals Announces Launch Date of Tarceva(R) (erlotinib) in Japan
|
(OSI Pharmaceuticals)
|
14-Dec-2007 |
| "Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Filed for Rheumatoid Arthritis in Europe
|
(Chugai)
|
03-Dec-2007 |
| "Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Filed for Rheumatoid Arthritis in the United States
|
(Chugai)
|
21-Nov-2007 |
| Roche Submits Application for FDA Approval of Actemra for the Treatment of Rheumatoid Arthritis
|
(Roche)
|
21-Nov-2007 |
| Newly Approved Administration of Cephalosporin Antibiotic Rocephin® for Injection: Once Daily Administration in Children
|
(Chugai)
|
19-Nov-2007 |
| A Second Overseas Phase III Trial Data Demonstrates Efficacy of "Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, in Rheumatoid Arthritis Patients
|
(Chugai)
|
08-Nov-2007 |
| Two Pivotal Phase III Studies for Roche’s ACTEMRA™ (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
|
(Roche)
|
07-Nov-2007 |
| Treatment with Pegasys Provides Hepatitis C Patients a Second Chance to Achieve a Cure After not Responding to Peg-intron
|
(Roche)
|
02-Nov-2007 |
| Treatment with PEGASYS®/COPEGUS™ Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron®/Ribavirin
|
(Roche)
|
02-Nov-2007 |
| Announcement of Supplemental Approval of Indication of Sigmart® Injection, a Treatment Drug for Unstable Angina Pectoris
|
(Chugai)
|
23-Oct-2007 |
| Anti-Cancer Agent Tarceva® Tablet, Approved in Japan
|
(Chugai)
|
22-Oct-2007 |
| Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan
|
(OSI Pharmaceuticals)
|
22-Oct-2007 |
| Chugai to Conduct Additional Clinical Trial for Additional Indication of the Recombinant Human Erythropoietin "Epogin® Injection" for Treatment of Chemotherapy-Induced Anemia
|
(Chugai)
|
27-Sep-2007 |
| Herceptin Eradicates Tumours and May Reduce the Need for Mastectomies in Women With Inflammatory HER2-Positive Breast Cancer
|
(Roche)
|
26-Sep-2007 |
| Positive Xeloda Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
|
(Roche)
|
25-Sep-2007 |
| Avastin Achieves Impressive Rate of Complete Resections (R0) in Patients With Advanced Colorectal Cancer
|
(Roche)
|
24-Sep-2007 |
| New Study Shows Once-Monthly Boniva is as Clinically Effective as Once-Weekly Fosamax at Increasing Bone Mineral Density in Postmenopausal Women with Osteoporosis
|
(Roche)
|
20-Sep-2007 |
| Actemra Monotherapy Demonstrates Significant Clinical Benefit in Patients with Rheumatoid Arthritis
|
(Roche)
|
25-Jul-2007 |
| Actemra: Latest Phase III Study Shows Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
|
(Roche)
|
10-Jul-2007 |
| ACTEMRA™ (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
|
(Roche)
|
10-Jul-2007 |
| Safety Measures for Oseltamivir Phosphate and Chugai’s Future Approach
|
(Chugai)
|
18-Jun-2007 |
| Overseas Phase III Trial Data Demonstrates Efficacy of "Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, in Rheumatoid Arthritis Patients
|
(Chugai)
|
15-Jun-2007 |
| Psoriasis Vulgaris Treatment Ethical Drug Topical Lotion Containing Active Vitamin D3 Launch of “Oxarol® Lotion”
|
(Chugai)
|
15-Jun-2007 |
| ACTEMRA™ (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
|
(Roche)
|
15-Jun-2007 |
| Actemra: Roche’s Novel Rheumatoid Arthritis Drug Shows Substantial Benefits for Patients in OPTION Study
|
(Roche)
|
15-Jun-2007 |
